FX-322 is Frequency’s lead product candidate, designed to regenerate auditory sensory hair cells in the cochlea and improve hearing in patients with sensorineural hearing loss (SNHL). A Phase 1/2 ...
Top-Line Results Show Consistent Drug Entry in All Patients WOBURN, Mass.--(BUSINESS WIRE)-- Frequency Therapeutics, Inc. (Nasdaq: FREQ), today announced top-line data from an exploratory clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results